Pacira Biosciences (NASDAQ:PCRX) had its target price hoisted by equities researchers at SVB Leerink from $45.00 to $58.00 in a research note issued to investors on Tuesday, The Fly reports. The brokerage presently has an “outperform” rating on the stock. SVB Leerink’s price target suggests a potential upside of 12.80% from the stock’s previous close.

A number of other analysts also recently commented on PCRX. BidaskClub downgraded Pacira Biosciences from a “buy” rating to a “hold” rating in a research note on Friday, May 29th. Stifel Nicolaus dropped their price objective on Pacira Biosciences from $49.00 to $48.00 and set a “hold” rating on the stock in a research note on Thursday, May 7th. Guggenheim assumed coverage on Pacira Biosciences in a research note on Tuesday, May 26th. They issued a “neutral” rating on the stock. Royal Bank of Canada reissued a “buy” rating and issued a $56.00 price objective on shares of Pacira Biosciences in a research note on Wednesday, May 13th. Finally, Needham & Company LLC dropped their price objective on Pacira Biosciences from $56.00 to $52.00 and set a “buy” rating on the stock in a research note on Thursday, April 30th. Eight equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $54.53.

Pacira Biosciences stock traded down $0.60 during mid-day trading on Tuesday, hitting $51.42. 122,513 shares of the company’s stock traded hands, compared to its average volume of 591,986. The firm has a 50 day moving average price of $44.53 and a 200 day moving average price of $42.09. The company has a quick ratio of 4.63, a current ratio of 5.37 and a debt-to-equity ratio of 0.94. The company has a market cap of $1.86 billion, a PE ratio of -2,569.72, a price-to-earnings-growth ratio of 2.22 and a beta of 1.31. Pacira Biosciences has a one year low of $27.46 and a one year high of $52.49.

Pacira Biosciences (NASDAQ:PCRX) last announced its earnings results on Thursday, May 7th. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.30 by $0.23. The firm had revenue of $105.68 million for the quarter, compared to the consensus estimate of $101.64 million. Pacira Biosciences had a positive return on equity of 13.89% and a negative net margin of 0.02%. The firm’s revenue for the quarter was up 15.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.22 EPS. On average, analysts expect that Pacira Biosciences will post 0.95 earnings per share for the current fiscal year.

In other news, VP Lauren Bullaro Riker sold 2,000 shares of Pacira Biosciences stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $45.26, for a total transaction of $90,520.00. Following the transaction, the vice president now owns 12,464 shares in the company, valued at $564,120.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Paul J. Hastings sold 2,025 shares of Pacira Biosciences stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $47.46, for a total value of $96,106.50. Following the transaction, the director now owns 4,856 shares in the company, valued at approximately $230,465.76. The disclosure for this sale can be found here. Insiders have sold 43,083 shares of company stock worth $2,019,772 over the last ninety days. 6.20% of the stock is owned by insiders.

Hedge funds have recently modified their holdings of the company. Acadian Asset Management LLC purchased a new position in shares of Pacira Biosciences during the first quarter valued at $25,000. C M Bidwell & Associates Ltd. acquired a new position in Pacira Biosciences during the first quarter valued at approximately $29,000. Sunbelt Securities Inc. acquired a new position in Pacira Biosciences during the fourth quarter valued at approximately $10,192,000. Quantbot Technologies LP acquired a new position in Pacira Biosciences during the fourth quarter valued at approximately $56,000. Finally, Amundi Pioneer Asset Management Inc. bought a new stake in shares of Pacira Biosciences during the first quarter worth $65,000.

About Pacira Biosciences

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.

Featured Story: What is a Buy-Side Analyst?

The Fly

Analyst Recommendations for Pacira Biosciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.